The estimated Net Worth of Tyler Brous is at least $888 mil dollars as of 27 June 2024. Tyler Brous owns over 8,416 units of Shattuck Labs stock worth over $888,068 and over the last 4 years Tyler sold STTK stock worth over $0.
Sign up
Tyler Brous STTK stock SEC Form 4 insiders trading
Tyler has made over 2 trades of the Shattuck Labs stock since 2022, according to the Form 4 filled with the SEC. Most recently Tyler bought 8,416 units of STTK stock worth $32,738 on 27 June 2024.
The largest trade Tyler's ever made was buying 8,416 units of Shattuck Labs stock on 27 June 2024 worth over $32,738. On average, Tyler trades about 1,824 units every 99 days since 2020. As of 27 June 2024 Tyler still owns at least 238,088 units of Shattuck Labs stock.
You can see the complete history of Tyler Brous stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Tyler Brous's mailing address?
Tyler's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Insiders trading at Shattuck Labs
Over the last 4 years, insiders at Shattuck Labs have traded over $14,634,250 worth of Shattuck Labs stock and bought 3,526,605 units worth $60,008,520 . The most active insiders traders include Group, Llc Green Jeremy Red..., Clay B Siegall, eJosiah Hornblower. On average, Shattuck Labs executives and independent directors trade stock every 25 days with the average trade being worth of $300,381. The most recent stock trade was executed by Tyler Brous on 27 June 2024, trading 8,416 units of STTK stock currently worth $32,738.
What does Shattuck Labs do?
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
What does Shattuck Labs's logo look like?
Complete history of Tyler Brous stock trades at Shattuck Labs
Shattuck Labs executives and stock owners
Shattuck Labs executives and other stock owners filed with the SEC include:
-
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
Chief Medical Officer -
Dr. Arundathy Nirmalini Pandite,
Chief Medical Officer -
Dr. Taylor H. Schreiber M.D., Ph.D.,
Co-Founder, CEO & Director -
Casi DeYoung,
Chief Bus. Officer -
Dr. Taylor H. Schreiber,
Co-Founder, CEO & Director -
Josiah C. Hornblower,
Co-Founder & Exec. Chairman -
Erin Ator Thomson J.D.,
Gen. Counsel -
Dr. Abhinav A. Shukla Ph.D.,
Chief Technical Officer -
Dr. Thomas Lampkin Pharm.D.,
Head of Regulatory Affairs -
Conor Richardson,
Director of Fin. -
Andrew R. Neill M.B.A.,
VP of Fin. & Corp. Strategy -
Amy Kate Sasser,
-
Michael Stewart Lee,
Director -
Arundathy N. Pandite,
Chief Medical Officer -
Casi De Young,
Chief Business Officer -
Abhinav A. Shukla,
Chief Technical Officer -
Group, Llc Green Jeremy Red...,
-
Taylor Schreiber,
Chief Executive Officer -
Erin Ator Thomson,
General Counsel -
Neil W Gibson,
-
Andrew R Neill,
Chief Financial Officer -
George Golumbeski,
-
Josiah Hornblower,
Director -
Tyler Brous,
-
Stephen Stout,
See Remarks -
Carrie Brownstein,
-
Clay B Siegall,